F-1/A: Baird Medical Files Amendment for Share Issuance and Resale, Potentially Diluting Share Value

Baird Medical is registering the issuance of shares upon warrant exercise and the resale of shares by existing securityholders, which could increase market volatility and dilute share value.

Summary

• Baird Medical Investment Holdings Limited has filed an amendment to its Form F-1 registration statement with the SEC.
• The filing covers the issuance of up to 11,500,000 ordinary shares upon the exercise of warrants at $11.50 per share.
• It also relates to the potential resale of up to 34,415,562 ordinary shares by selling securityholders.
• These shares include those held by Betters Medical Investment Holdings Limited, ExcelFin SPAC LLC, J.V.B. Financial Group, LLC, and Grand Fortune Capital (H.K.) Company Limited.
• The selling securityholders may offer these shares from time to time through public or private transactions at prevailing market prices or negotiated prices.
• The company will not receive any proceeds from the sale of shares by the selling securityholders, but will receive proceeds from warrant exercises.
• The likelihood of warrant exercises is low, given the current share price of $5.42 on January 16, 2025, is below the exercise price.
• The sale of a significant number of shares by selling securityholders could increase market volatility or result in a decline in the share price.
• The company is subject to legal and operational risks associated with having substantial operations in China.
• The company has completed the filing procedures in connection with the business combination with ExcelFin under the Overseas Listing Trial Measures on January 2, 2024.
• The company may need to complete filing procedures for future offshore fund-raising activities.
• The company is an emerging growth company and a foreign private issuer, which allows it to comply with certain reduced reporting requirements.
• Ms. Haimei Wu is the beneficial owner of 50.4% of the voting power, making the company a controlled company under Nasdaq rules.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the company's market position and growth strategies, it also acknowledges potential risks, including market volatility, regulatory challenges, and dependence on key personnel. The financial results show a decrease in revenue and net income, which tempers the positive aspects.

Positives

• The company has completed the filing procedures in connection with the business combination with ExcelFin under the Overseas Listing Trial Measures on January 2, 2024.
• The company is an emerging growth company and a foreign private issuer, which allows it to comply with certain reduced reporting requirements.

Negatives

• The likelihood of warrant exercises is low, given the current share price of $5.42 on January 16, 2025, is below the exercise price.
• The sale of a substantial number of shares by selling securityholders could increase market volatility or result in a decline in the share price.
• The company is subject to legal and operational risks associated with having substantial operations in China.

Risks

• The sale of a substantial number of securities by the Selling Securityholders, or the perception of such sales, could cause the market price for our Ordinary Shares to decline.
• We face various legal and operational risks and uncertainties related to being based in and having significant operations in China, and therefore are subject to risks associated with doing business in China generally.
• Our securities may be delisted under the HFCAA if the PCAOB is unable to inspect auditors who are located in mainland China and Hong Kong.
• The filing with the CSRC may be required in connection with future overseas fund-raising activities, and we cannot predict whether we will be able to obtain such approval or complete such filing.

Future Outlook

The company intends to broaden its product portfolio, enhance research and development capabilities, and expand its presence in foreign and emerging markets.

Industry Context

The company operates in the microwave ablation medical device industry, which is experiencing growth in China and has potential in overseas markets like the U.S. and Europe.

Comparison to Industry Standards

• The company ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022 according to the Frost & Sullivan Report.
• The company was the third largest microwave ablation medical device provider in the PRC in terms of sales revenue in 2022.
• The top four microwave ablation manufacturers account for about 88.4% of the sales in 2022.
• The company's main competitors are ECO Medical, Vison Medical, and Canyon Medical.

Related Party Transactions

• Haimei Wu, our Chairwoman and Chief Executive Officer, is the legal owner of the premises to which our Tianhe District Usage Certificate was granted, which premises are also co-occupied by the Guangdong branch office of Baide Suzhou.
• Our use of the Taicang Plant is conducted pursuant to a sublease agreement to which certain affiliated entities are parties.
• In 2023, three of Betters Medicals preference shares holders elected to exercise their right to require Betters Medical, Haimei Wu and certain shareholders of Betters Medical, on a joint and several basis, to repurchase or purchase 100% of their preference shares.
• We are party to a Subscription Agreement dated June 30, 2021, and certain of our affiliates, as well as the Shareholders Agreement.

Stakeholder Impact

• Shareholders may experience dilution and increased market volatility.
• The company's ability to pay dividends may be limited by PRC regulations.
• The company's future performance is subject to various risks and uncertainties.

Next Steps

• The company will continue to pursue product registration testing and clinical trials for its pipeline products.
• The company plans to expand its presence in foreign and emerging markets.
• The company will continue to monitor and comply with evolving regulations in China.

Key Dates

Keywords

ordinary shares, selling securityholders, warrants, business combination, China, PCAOB, CSRC, HFCAA, filing